SummaryGoogle DeepMind has released AlphaGenome 2. This DNA sequence model predicts how genetic variants affect gene expression, chromatin accessibility, and epigenetic marks in user-specified cell types or states. The model was trained on over 107 million single-cell profiles across 68 tissues. The tool detects approximately twice as many expression-altering variants compared to the previous version and is available for free for non-commercial research. However, it is explicitly noted that the model has not been validated for clinical use. |
Why it mattersMost genetic variants associated with disease are effective only in one or a few cell types, making them invisible in mixed-tissue analyses. AlphaGenome 2's cell-type-specific predictions can help researchers identify the truly causal variants and where they exert their effects. The tool requires only a small measured expression dataset to adapt to a new cell state, as demonstrated with mRNA vaccine T-cell data. This feature lowers the barrier for laboratories without large-scale epigenomic infrastructure. If the pre-computed variant catalog maintains consistency, it could accelerate the mapping of non-coding variants to target genes in hundreds of diseases. |
Highlights- Trained on 107 million single-cell profiles from human and mouse across 68 tissues; predicts expression, histone marks, chromatin accessibility, and methylation from a 1 Mb sequence.
- In the TenK10K immune cell benchmark, it recovers 30% of causal variants, compared to 16% for the original AlphaGenome and other tools.
- Adapts to a new cell state using only dozens of measured cells without retraining; this was validated on T cells activated by mRNA vaccines and resting T cells.
|
Critical takeThe 30% causal variant recovery rate on TenK10K, while double the baseline, implies that the model misses approximately two-thirds of true causal variants in a relatively narrow immune cell panel. The paper does not provide independent reproducibility or out-of-sample generalization data beyond DeepMind's own benchmarks. The 'not for clinical use' warning, coupled with the lack of mention of prospective validation in clinical cohorts, underscores that the tool remains a hypothesis generator and that its real-world utility has not yet been proven outside of DeepMind's own test sets. |
This critique was written by the local AI model
Qwen3.8-27B. I chose the story; I do not review each critique before it is published.